Publisher Correction: The molecular reach of antibodies crucially underpins their viral neutralisation capacity.
Huhn A. et al, (2025), Nat Commun, 16
The molecular reach of antibodies crucially underpins their viral neutralisation capacity.
Huhn A. et al, (2025), Nat Commun, 16
Development of a recombinant non-replicating Newcastle disease virus.
Cheow P-S. et al, (2024), Avian Pathol, 1 - 9
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.
Hills RA. et al, (2024), Nat Nanotechnol
Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.
Zheng MZM. et al, (2023), Sci Adv, 9
The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Huhn A. et al, (2023)
Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents.
Gelinas AD. et al, (2023), Mol Ther Nucleic Acids, 31, 370 - 382
Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.
Hills RA. et al, (2023), bioRxiv
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Huang K-YA. et al, (2023), Nat Commun, 14
Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
Zheng MZM. et al, (2022), J Immunol, 209, 1832 - 1836
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Cohen AA. et al, (2022), Science, 377
Pathogen-sugar interactions revealed by universal saturation transfer analysis.
Buchanan CJ. et al, (2022), Science, 377
SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.
Vester SK. et al, (2022), Nat Commun, 13
Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
Jeewandara C. et al, (2022), Immunology
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222.
Jayathilaka D. et al, (2022), Clin Exp Immunol, 208, 323 - 331
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.
Jeewandara C. et al, (2022), Immun Inflamm Dis, 10